Pipeline

February 26, 2018

Company	Drug/Device	Medical Condition	Status
Arch Biopartners	AB569	antibiotic-resistant bacterial infections in the lungs of cystic fibrosis and chronic obstructive pulmonary disease	Phase I trials initiated in the U.S.
Xencor	XmAb18087	neuroendocrine tumors (NET) and gastrointestinal stromal tumors (GIST)	Phase I trials initiated
PQ Bypass	DETOUR	Long (>15 cm) superficial femoral artery (SFA) blockages	Phase I trials initiated enrolling 292 subjects in the U.S. and Europe
Therachon	TA-46	achondroplasia	Phase I trials initiated enrolling 70 subjects in the Netherlands
OncoPep	PVX-4106	metastatic triple negative breast cancer (TNBC) who are human leukocyte antigen A2 positive (HLA-A2+)	Phase Ib trials initiated
Bonti	EB-001	scar reduction	Phase II trials initiated
AbbVie	JAK1-selective inhibitor	adult patients with moderate to severe atopic dermatitis	Phase II trials initiated
IRX Therapeutics	IRX-2	squamous cervical intraepithelial neoplasia 3 or vulvar intraepithelial neoplasia 3	Phase II trials initiated
Glenmark Pharmaceuticals	GBR 830	moderate to severe atopic dermatitis	Phase IIa trials initiated enrolling 64 subjects
Centrexion Therapeutics	CNTX-4975	Chronic moderate to severe knee osteoarthritis	Phase III trials initiated enrolling 325 subjects
AstraZeneca	IMFINZI®	unresectable Stage III non-small cell lung cancer following CRT	Phase III trials initiated
Celgene	OTEZLA \(apremilast)	active Behçet’s Disease	Phase III RELIEF trials initiated
Vertex Pharmaceuticals Incorporated	VX-659	cystic fibrosis	Phase III trials initiated enrolling 360 patients
Eli Lilly	Taltz (ixekizumab)	moderate to severe genital psoriasis	Phase IIIb trials initiated enrolling 149 subjects
Evofem Biosciences	Amphora	urogenital chlamydia infection in women	Fast Track designation granted by the FDA
Novartis	Cosentyx (secukinumab)	moderate to severe plaque psoriasis	FDA approved label update